The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Lebkowski Jane since 2006.
The trader's CIK number is 1187035.
At the time of the last reporting, Lebkowski Jane was the SVP Regen Medicine of Asterias Biotherapeutics, Inc.. (stock ticker symbol AST).
Also see all insider trading activities at Asterias Biotherapeutics, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2015 | AST | 0 | $0 | 4,912 | $29,472 | 0 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2011 | GERN | 0 | $0 | 28,237 | $121,419 | 0 | $0 |
2010 | GERN | 0 | $0 | 12,953 | $69,586 | 0 | $0 |
2009 | GERN | 0 | $0 | 25,230 | $152,997 | 0 | $0 |
2008 | GERN | 0 | $0 | 8,911 | $47,584 | 0 | $0 |
2006 | GERN | 0 | $0 | 10,676 | $91,386 | 0 | $0 |
1. Asterias Biotherapeutics, Inc. (AST)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2015-09-15 | AST | Sale | 4,912 | 6.00 | 29,472 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2011-06-14 | GERN | Sale | 25,262 | 4.28 | 108,121 |
2011-05-24 | GERN | Sale | 2,975 | 4.47 | 13,298 |
2010-06-02 | GERN | Sale | 10,617 | 5.43 | 57,650 |
2010-05-24 | GERN | Sale | 2,336 | 5.11 | 11,936 |
2009-05-29 | GERN | Sale | 2,277 | 6.35 | 14,458 |
2009-05-26 | GERN | Sale | 14,092 | 6.75 | 95,121 |
2009-01-05 | GERN | Sale | 8,861 | 4.90 | 43,418 |
2008-01-04 | GERN | Sale | 8,911 | 5.34 | 47,584 |
2006-01-09 | GERN | Sale | 10,676 | 8.56 | 91,386 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Lebkowski Jane (SVP Regen Medicine of Asterias Biotherapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.